Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest Content
Archive
For authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest Content
Archive
For authors
About
Podcasts
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 8, Issue 2
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Lupus
Original research
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
Online download statistics by month:
Online download statistics by month: October 2022 to October 2023
Abstract
Full
Pdf
Oct 2022
264
264
97
Nov 2022
763
754
231
Dec 2022
195374
195375
581
Jan 2023
3381
3374
143
Feb 2023
2060
2057
119
Mar 2023
2324
2319
126
Apr 2023
1471
1466
113
May 2023
1245
1238
140
Jun 2023
2027
2019
97
Jul 2023
2183
2173
87
Aug 2023
2279
2257
114
Sep 2023
1880
1863
104
Oct 2023
1581
1572
130
Total
216832
216731
2082
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF